Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can early COVID-19 drugs keep high-risk patients out of the hospital?

NCT ID NCT04356495

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving early treatment to adults with COVID-19 who have risk factors (like age over 60 or high blood pressure) could prevent them from needing oxygen, hospitalization, or dying. About 412 people took part. The goal was to see if these treatments are safe and effective for use at home.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

412 people

The number who actually took part.

Started

Jul 2020

Finished

Oct 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical picture suggestive of COVID-19 dated 7 days or less. * Positivity of a test proving an acute SARS-CoV-2 infection, according to current recommendations. * Absence of criteria for hospitalization or oxygen therapy according to current recommendations. * Age : * greater than or equal to 60 years of age without any risk factor * or between 50 and 59 years of age and the presence of at least one of the following risk factors : * Arterial hypertension under treatment (all stages) * Obesity (BMI ≥30 kg/m2) * Diabetes under treatment (all types) * Ischemic heart disease (all stages) * Heart failure (all stages) * Stroke History * Chronic Obstructive Pulmonary Disease (all stages) * Stage 3 chronic renal failure (30 ≤ Estimated GFR \< 60 mL/min/1.73 m²) * Malignancies (solid tumours or blood malignancies) that are progressive or were diagnosed less than 5 years ago. * Immunodeficiency * of therapeutic origin (solid organ transplant or hematopoietic stem cell transplant, cancer chemotherapy, immunosuppressive therapy, corticosteroids \> 15 mg/d of prednisone equivalent taken for at least 2 months); * HIV infection with CD4\<200/mm3. * Valid, ambulatory person, fully able to understand the issues of the trial * Beneficiary of a Social Security scheme * Signed informed consent Exclusion Criteria: * Asymptomatic person * Inability to make a decision to participate (dementia, person under legal protection, curatorship or guardianship) * Ongoing illness or chronic treatment contraindicated by taking one of the trial drugs.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Corona virus infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19 Orthocoronavirinae infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Corona virus infection SARS-COV2

Contacts and locations

Locations

  • Bordeaux university Hospital

    Bordeaux, 33000, France

  • CHRU de Nancy

    Nancy, France

  • CHU de Dijon-Bourgogne

    Dijon, France

  • CHU de Montpellier

    Montpellier, 34295, France

  • CHU de Toulouse

    Toulouse, France

  • CNGE

    Paris, France

  • Groupe hospitalier Paris Saint Joseph

    Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.